Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;24(135):23-9.
doi: 10.1183/09059180.00011014.

Advances in target therapy in lung cancer

Jean-Paul Sculier  1 , Thierry Berghmans  2 , Anne-Pascale Meert  2
Affiliations
Review

Advances in target therapy in lung cancer

Jean-Paul Sculier et al. Eur Respir Rev. 2015 Mar.

Abstract

Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib), anaplastic lymphoma kinase rearrangements (e.g. crizotinib) or angiogenesis (drugs under development), or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab) or epidermal growth factor receptors (e.g. cetuximab). The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Berghmans T, Cortot A, CsToth I, et al. . Les recommandations de pratique clinique de l'European Lung Cancer Working Party: Mises à jour. [Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]. Rev Med Brux 2014; 35: 132–133. - PubMed
    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132. - PubMed
    1. Thatcher N, Chang A, Parikh P, et al. . Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527–1537. - PubMed
    1. Lynch TJ, Bell DW, Sordella R, et al. . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139. - PubMed
    1. Travis WD, Brambilla E, Noguchi M, et al. . International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244–285. - PMC - PubMed

MeSH terms